Ondine Biomedical Inc
LSE:OBI
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
O
|
Ondine Biomedical Inc
LSE:OBI
|
53.1m GBP |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
190.8B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
173.9B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
116.7B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
106.2B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.6B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
48.5B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.8B USD |
Loading...
|
Market Distribution
| Min | -10 058.3% |
| 30th Percentile | 20.4% |
| Median | 33.6% |
| 70th Percentile | 50.5% |
| Max | 717.4% |
Other Profitability Ratios
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Ondine Biomedical Inc is 65.8%, which is above its 3-year median of 59.5%.
Over the last 3 years, Ondine Biomedical Inc’s Gross Margin has increased from 45.9% to 65.8%. During this period, it reached a low of 45% on Dec 31, 2022 and a high of 65.8% on Jun 30, 2025.
